Skip to content

Press Releases

 
Press Releases
All Releases
Nov 12, 2014
Presentation and Webcast on Wednesday, November 19, 2014 at 11:30 a.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprote...
Nov 11, 2014
Event to be held in Chicago, location of 2014 American Heart Association Scientific Sessions Webcast on Monday, November 17, 2014 at 7:30 p.m. Central Time/8:30 p.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NAS...
Nov 10, 2014
Conference Call and Webcast on Monday, November 10, 2014 at 4:30 p.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotei...
Nov 5, 2014
Presentation on Tuesday, November 11, 2014 at 8:00 a.m. Mountain Time/10:00 a.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density...
Nov 3, 2014
Conference Call and Webcast on Monday, November 10, 2014 at 4:30 p.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotei...
Oct 21, 2014
ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometab...
Oct 15, 2014
ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometab...
Oct 14, 2014
ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometab...
Oct 1, 2014
- ETC-1002-008 study meets primary endpoint - - LDL-cholesterol lowering significantly greater with ETC-1002 than ezetimibe - - ETC-1002 appears to be safe and well tolerated - Conference Call and Webcast on Wednesday, October 1, 2014 at 4:30 p.m. Eastern T...
Sep 22, 2014
Webcast on Friday, September 26, 2014 at 8:30 a.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR) a clinical-stage emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol ...
Aug 12, 2014
Conference Call and Webcast on Tuesday, August 12, 2014 at 4:30 p.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ:ESPR) a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipo...
Aug 5, 2014
Conference Call and Webcast on Tuesday, August 12, 2014 at 4:30 p.m. Eastern Time ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR) a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lip...
Jul 24, 2014
ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hyperchole...
Jul 16, 2014
ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announ...
Jun 26, 2014
ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announ...
= add release to Briefcase